Mitoxantrone
Back to searchMolecule Structure
Scientific Name
Mitoxantrone
Description of the Drug
Mitoxantrone is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01204
http://www.drugbank.ca/drugs/DB01204
Brand Name(s)
Mitoxantrone HCl, Novantrone
Company Owner(s)
Fresenius Kabi Usa Llc, Mylan Laboratories Ltd, Hikma Pharmaceuticals Usa Inc, Teva Pharmaceuticals Usa, Fresenius Kabi Oncology Plc, Hospira Worldwide, Inc, Emd Serono Inc, Rising Pharma Holdings Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
| DNA topoisomerase II alpha | SINGLE PROTEIN | INHIBITOR | CHEMBL1806 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3000 | ||||||||
| PharmGKB | PA450526 | ||||||||
| Human Metabolome Database | HMDB0015335 | ||||||||
| DrugBank | DB01204 | ||||||||
| PubChem: Thomson Pharma | 14857298 | ||||||||
| PubChem | 4212 | ||||||||
| Mcule | MCULE-5513787065 | ||||||||
| LINCS | LSM-2481 | ||||||||
| Nikkaji | J19.969I | ||||||||
| PDBe | MIX | ||||||||
| BindingDB | 67690 | ||||||||
| EPA CompTox Dashboard | DTXSID4046947 | ||||||||
| DrugCentral | 1821 | ||||||||
| Brenda | 132934 | 127071 | 224533 | 8142 | 125891 | 229661 | 11262 | 229662 | 226500 |
| ChemicalBook | CB1246423 | ||||||||
| Guide to Pharmacology | 7242 | ||||||||
| rxnorm | MITOXANTRONE | MITOXANTRONE HYDROCHLORIDE | |||||||
| KEGG Ligand | C11195 | ||||||||
| ChEBI | 50729 | ||||||||
| ZINC | ZINC000003794794 |
